gms | German Medical Science

43. Kongress der Deutschen Gesellschaft für Rheumatologie, 29. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie, 25. Wissenschaftliche Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie

02.-05. September 2015, Bremen

Update on results of the uveitis outcome validation study from the multinational interdisciplinary working group for uveitis in childhood (MIWGUC)

Meeting Abstract

  • Ivan Foeldvari - Schön Klinik Hamburg-Eilbek, Hamburger Zentrum für Kinder- und Jugendrheumatologie, Hamburg
  • Sandra Schenck - Deutsches Rheuma-Forschungszentrum (DRFZ), Programmbereich Epidemiologie, Berlin
  • Gabriele Simonini - Universita degli studi Firenze, Firenze, Italy
  • Cinzia de Libero - Ospedale Meyer, Firenze, Italy
  • Gabriele Brumm - University Hospital, Ophthalmology, Hamburg
  • Kaisu Kotaniemi - University Childrens Hospital, Ophthalmology, Helsinki, Finnland
  • Susan Nielsen - Juliane Marie Centret, Rigshospitalet, Pediatric Rheumatology, Copenhagen, Danmark
  • Regitze Bangsgaard - Juliane Marie Centret, Rigshospitalet, Copenhaven, Denmark
  • Irene Pontikaki - Università di Milano - Istituto Gaetano Pini, Milano, Italy
  • Valeria Gerloni - Università di Milano - Istituto Gaetano Pini, Milano, Italy
  • Elisabetta Miserocchi - Università Vita-Salute, Scientific Institute San Raffaele, Milano, Italy
  • Martina Niewerth - Deutsches Rheuma-Forschungszentrum (DRFZ), Programmbereich Epidemiologie, Berlin
  • Arndt Heiligenhaus - Augenklinik, Münster

Deutsche Gesellschaft für Rheumatologie. Deutsche Gesellschaft für Orthopädische Rheumatologie. Gesellschaft für Kinder- und Jugendrheumatologie. 43. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh); 29. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh); 25. wissenschaftliche Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR). Bremen, 02.-05.09.2015. Düsseldorf: German Medical Science GMS Publishing House; 2015. DocKR.02

doi: 10.3205/15dgrh126, urn:nbn:de:0183-15dgrh1261

Veröffentlicht: 1. September 2015

© 2015 Foeldvari et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.


Gliederung

Text

Introduction: Juvenile idiopathic arthritis associated uveitis (JIAU) is one of the most severe comorbidities and occurs in around 10% of patients. There are currently no specific established outcome measures for JIAU. Adopting the part of the SUN-criteria, we developed and proposed specific outcome measures for JIAU.

Methods: Patients were considered eligible, if they started a nonbiologic or biologic disease modifying agent, as indicated by active the uveitis. At baseline, follow up at 3 months and at 6 months following parameters were collected: demographics, rheumatologic assessment, ophthalmologic assessment.

Results: 49 patients were included in the study and 35 patients had a complete follow-up for at least at 6 months. 34/49 (69%) of the patients were female. The mean age at inclusion into the study was 8.4 years (SD=3.4). 98% of the patients were Caucasian. At inclusion the median disease duration of JIA was 52 months for arthritis and 33 months for uveitis. All patients had anterior uveitis. The left eye was more frequently involved (95.3%) then the right eye (81%). Cellcount at baseline was +1 or more in 65.1% of the right eyes and 68.9% of the left eyes, and at 6 months only 22.6% in the right and 19.3% in the left eyes. The cell count before dilatation (p=0.008) and after dilatation (p<0.001) improved significantly over time. Flare was ≥1+ (graded by SUN) at baseline in the right eyes in 76.7% and in the left eyes 70.2% and at 6 months at the right eyes in 24.1% and the left eyes in 24.1%. The flare grade according SUN (p<0.001) improved significantly comparing time point zero to 6 months. The VAS score (0-100) for uveitis related disability decreased from 40.8 to 17.5 (p=0.002) and JIA associated disability, decreased from 34.1 to 8.3 (p<0.001).

Conclusion: These results are promising. The newly suggested Uveitis disability, cell count and flare grade showed significant changes after 6 months. Further evaluation of these items and the other suggested items will help to establish standardized measures to assess the activity of uveitis and the efficacy of a drug in treatment trials.